Stereotaxis 3Q 2026: Revenue $8.93M, EPS ($0.07) — 10-Q Summary
Stereotaxis reported 3Q 2026 revenue of $8.93M, up 20% YoY, driven by higher system sales. Net loss was $6.8M, slightly wider than the prior year. Gross margin fell to 44% from 55% due to product mix. Robocath acquisition contributed minimal revenue and a $1.6M net loss.
How this was made

The 30-second read
Why it matters
Investors will likely focus on whether system sales growth can offset gross margin compression and whether Robocath’s early post-acquisition losses are temporary versus indicative of longer-term cost structure.
Market read
A fresh quarterly print with explicit margin and acquisition-integration details can shift expectations for near-term profitability and acquisition value.
What to watch
Gross margin decline is attributed to product mix; traders may want to separate mix effects from structural margin deterioration and watch whether disposables growth offsets system margin pressure.
Background
The piece is a short 10-Q summary for Stereotaxis’ 3Q 2026, including segment revenue drivers and the July 7 Robocath acquisition’s early contribution.
Ticker impact
Stereotaxis reports 3Q 2026 revenue of $8.93M and diluted EPS of ($0.07), with gross margin falling to 44% and Robocath losses post-close.
Likely downside bias as investors weigh higher system sales against lower gross margin and Robocath’s $1.6M net loss contribution.
The article provides fresh quarterly datapoints (revenue, EPS, gross margin, and Robocath post-close contribution) that directly affect earnings power and acquisition integration expectations.
Market effects
Highlights margin sensitivity in medical device systems and the integration cost profile of acquired robotics/disposables businesses.
No clear regional spillover indicated beyond US-listed small-cap medtech sentiment.
Limited global relevance; story is company-specific with acquisition integration details.
Counterpoint
Revenue growth driven by systems could still indicate improving demand, and the Robocath post-close revenue is minimal, so losses may normalize as integration progresses.
Key entities
- companyStereotaxis, Inc.
US-listed medical device company reporting 3Q 2026 revenue, EPS, gross margin, and early Robocath acquisition contribution.
- acquired businessRobocath
Acquisition closed July 7; contributed less than $0.1M revenue and a $1.6M net loss post-acquisition per the summary.

